TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00594945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 1 Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 1 Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: 1 Dose
Study: NCT04195191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANM
Description: communication intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: regular assistance in community pharmacies
Study: NCT00745849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40mg by mouth twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02656680

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Continuous Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. For this arm, the study team will keep recruitment open for this condition to allow enrollment of new participants through week 8.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Closed Enrollment
Description: Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
Study: NCT01143389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UVX light
Description: UVX 365 nm wavelength light source is applied with continued application of riboflavin.
Study: NCT03502109

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review with follow-up
Description: Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
Study: NCT01955304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
Study: NCT03120273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Injection
Description: 15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole Injection
Description: 30 mg q12h for 5 days.
Study: NCT02386774

Intervention type: DEVICE
Group type: OTHER
Intervention: Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)
Description: used for Multifluorescence IVCM~* anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~* Fluorescein 0,5%, Rose Bengal , Infracyanine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: microangiography
Description: realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: microangiography
Description: realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
Study: NCT00644592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate capsule daily for 4 weeks
Description: Placebo capsule daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate capsule daily for 4 weeks
Description: Placebo capsule daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 160 mg/day orally for 4 weeks
Study: NCT00261040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Surgery
Description: In minimally invasive surgery, the surgeon makes a shorter incision (about 10 cm or less) along the side of the thigh and replaces the hip through this smaller incision. The surgeon is able to do the surgery through a shorter incision by using special instruments which can guide him or her.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Surgery
Description: The standard way that an orthopaedic surgeon performs a hip replacement surgery is that they make a long incision (about 20 cm) down the side of the thigh and then replaces the hip joint through this long incision.
Study: NCT01695746

Intervention type: DRUG
Intervention: C.E.R.A.
Description: Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
Study: NCT03847207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0030310
Description: Solution for Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0030310
Description: Solution for Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 600 μg for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo Solution
Study: NCT00644592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 160 mg/day orally for 4 weeks
Study: NCT01262898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040 (5 mg tablet)
Description: 5 mg tablet
Study: NCT02641041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: single or multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: single or multiple dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB033
Description: single or multiple dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or multiple dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or multiple dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or multiple dose
Study: NCT02632942

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAQ criteria
Description: Obliteration of accessory vein which satisfy the HAQ criteria as below:~1. 60% or greater diameter of the main AVF~2. 50% diameter of AVF with at least one more av\>40% in diameter.~3. 50% in diameter and divides into branches of same size.~4. av likely to interfere with cannulation on physical examination.~5. \>30% in diameter and associated with stenosis at site of origin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Recommendation
Description: Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
Study: NCT00439634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1625
Description: oral administration
Study: NCT04170933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic recanalization
Description: 1. Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~2. Perform endoscopic sphincterotomy (EST).~3. Place one magnet above the stricture through the PTCD fistula.~4. Introduce another magnet below the stricture through the common bile duct with ERCP.~5. Place the magnets at the appropriate point to attract each other.~6. The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~7. A plastic stent will be placed in the bile duct for lasting support.
Study: NCT06398691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nazal CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated humidified high-flow air support with nasal cannula
Study: NCT00005849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Study: NCT00439634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1625
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1625
Description: oral administration
Study: NCT00005849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02605239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleaching teeth
Description: bleaching teeth with carbamide peroxide 10% for 3 weeks
Study: NCT01370915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin (Lyrica)
Description: Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin complex (placebo)
Description: Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
Study: NCT03344393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: intravenous ketamine infusion intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: intravenous normal saline infusion intraoperatively
Study: NCT01860404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: The three BCAA's will be combined together and dissolved in a flavored solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: The three BCAA's will be combined together and dissolved in a flavored solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: The three BCAA's will be combined together and dissolved in a flavored solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: The three BCAA's will be combined together and dissolved in a flavored solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
Study: NCT02627807

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT using individualized CTV
Description: Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
Study: NCT00439634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study: NCT03751345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely
Description: PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
Study: NCT02627807

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT using traditional CTV
Description: Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and cisplatin (induction chemotherapy)
Description: Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Indirect calorimetry, accelerometer and seven-day dietary recall
Description: Energy availability assessment.
Study: NCT02627807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 100mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 80mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 80mg/m² concurrent chemotherapy
Description: Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
Study: NCT03437954

Intervention type: OTHER
Group type: OTHER
Intervention: Diet modification
Description: Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Diet modification
Description: Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
Study: NCT02588365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active)
Description: Online computer games targeting attention, EF, and problem-solving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Passive)
Description: Online computer games targeting attention, EF, and problem solving

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active or Passive)
Description: Online computer games targeting attention, EF, and problem solving
Study: NCT04529408

Intervention type: DEVICE
Intervention: EarSats Pulse Oximeter Probe
Description: Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test

Intervention type: DEVICE
Intervention: EarSats Pulse Oximeter Probe
Description: Off-the-shelf pulse oximeter embedded into a memory foam ear plug for measuring blood oxygen saturation (SpO2) from the ear canal; in-ear SpO2 measured at-rest and during 6 minute walk test
Study: NCT02504164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam 0.02mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No premedication
Description: No premedication before sedation for endoscopic submucosal dissection
Study: NCT04543864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric intraoral welding device
Description: welding metal framework to the implants in completely edentulous maxilla by electric welding device intraorally

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: casting
Description: casting the metal framework
Study: NCT02260271

Intervention type: OTHER
Intervention: Database Entry/Biospecimen Collection
Description: blood, urine, buccal samples and medical data collected
Study: NCT03108690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics .
Description: Beta-lactam antibiotic will be administered as continous infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring of beta-lactam antibiotics.
Description: Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
Study: NCT03006679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam
Description: meropenem 2 g and vaborbactam 2 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam
Description: meropenem 2 g and vaborbactam 2 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: piperacillin 4 g and tazobactam 0.5 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/Tazobactam
Description: piperacillin 4 g and tazobactam 0.5 g
Study: NCT05538845

Intervention type: DEVICE
Intervention: Screw fixation
Description: Screw fixation to patients

Intervention type: DEVICE
Intervention: Suture button
Description: Suture button for patients
Study: NCT04217980

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasonography (LUS) or Chest X ray (CXR)
Description: pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) or Chest X ray (CXR)
Description: pediatrician researcher (PR) will conduct a LUS or CXR at admission time as a first test of lung image depending on randomized group.
Study: NCT02395770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching \& Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports
Study: NCT02907827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow up DW MRI
Description: Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow up DW MRI
Description: Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis